More children under 12 in US are being prescribed weight-loss drugs, study finds

GLP-1 weight-loss prescriptions for U.S. children aged 8-11 with obesity rose from 0.03% in 2019 to 9.3% in June, a more than 300-fold increase, according to a Pediatrics study of over 3.5 million children. Of the 20,282 children treated during the study period, most received Novo Nordisk's Wegovy, while Novo's Saxenda and Eli Lilly's Zepbound were also prescribed. The accelerating off-label use supports longer-term demand for GLP-1 therapies, although long-term safety monitoring and access disparities remain material risks.

Analysis

The investable implication is not near-term pediatric revenue but a gradual expansion of the treated-obesity funnel and earlier patient lifetime value. NVO appears better positioned than LLY for the initial benefit because its obesity franchise has deeper pediatric clinician familiarity; however, this is unlikely to move FY2026 estimates materially given the small addressable population, dose titration, and inconsistent payer coverage. The more important 6-18 month signal is that real-world pediatric adoption may pressure commercial and Medicaid plans to formalize coverage criteria, creating a reimbursement catalyst for both NVO and LLY but also raising scrutiny of net pricing.

The asymmetry is regulatory and reputational rather than demand-driven. Long-duration treatment in young patients creates a much higher bar for safety evidence: any signal involving growth, psychiatric events, pancreatitis, or treatment discontinuation could trigger label restrictions and compress obesity-franchise multiples well beyond the direct revenue exposure. Conversely, a formal pediatric-label expansion or broad state Medicaid coverage would validate a materially longer treatment duration and enlarge the market. The access skew also argues against extrapolating current prescription growth into volume forecasts; payer utilization management, not physician demand, is the binding constraint.

Consensus may be over-crediting this data point as incremental upside for GLP-1 leaders. Pediatric demand is highly visible politically, but it can intensify public debate around affordability and force rebates, especially if states absorb more coverage. For NVO and LLY, the relevant monitoring items are pediatric trial readouts, FDA labeling actions, state Medicaid formulary changes, and whether gross-to-net deterioration offsets prescription growth.

Key Decisions for Investors

• Maintain a modest long NVO / short LLY relative-value position over the next 1-3 months only if NVO continues to demonstrate superior obesity volume growth; the pediatric channel marginally favors NVO, while LLY retains supply and efficacy advantages. Exit if NVO's obesity prescription trend underperforms LLY for two consecutive monthly datasets or if NVO guides to worsening net-price pressure.
• Do not add outright GLP-1 exposure solely on this evidence: pediatric utilization remains too small to support a meaningful FY2026 revenue-estimate revision. Set alerts for FDA pediatric-label developments and state Medicaid coverage announcements; those are the events that could warrant upgrading the thesis.
• For existing NVO and LLY longs, consider 6-12 month downside protection around pediatric safety-data and regulatory milestones, where an adverse signal could cause sector-wide multiple compression disproportionate to direct sales impact.
• Watch managed-care names UNH, CVS, and ELV for a second-order negative: broader pediatric coverage would raise pharmacy-benefit cost exposure before rebate negotiations catch up. This is a monitor rather than a short until formulary commitments or medical-loss-ratio guidance revisions become visible.